Roche's Rheumatoid Arthritis Drug Actemra Fails to Help COVID-19 Patients With Pneumonia

AIFA, Italy's drug-regulation agency, said Roche's (OTC: RHHBY) rheumatoid arthritis drug Actemra didn't help patients with early-stage COVID-19 pneumonia in an Italian clinical trial that it authorized.

An interim look at the first 126 patients enrolled in the study found that the drug didn't reduce severe respiratory symptoms, intensive-care visits, or death, compared to standard of care, so the clinical trial was stopped early.

Image source: Getty Images.

Continue reading

Source Fool.com